Share：
Share this content in WeChat
X
[Chinese][PDF]67434
• Review •
Progress of MRI in predicting of the tumor response after neoadjuvant chemoradiotherapy for rectal cancer
LIU Dan  ZHANG Shengchao 

Cite this article as: Liu D, Zhang SC. Progress of MRI in predicting of the tumor response after neoadjuvant chemoradiotherapy for rectal cancer[J]. Chin J Magn Reson Imaging, 2022, 13(9): 163-166. DOI:10.12015/issn.1674-8034.2022.09.039.


[Abstract] Because patients with locally advanced rectal cancer cannot directly remove the lesions, after neoadjuvant chemoradiotherapy (nCRT), some people have a more sensitive response, and a complete tumor response will occur. Therefore, local resection or "watch and wait" approach is expected to replace surgical resection for such patients, thereby preserving the patient's anus and avoiding unnecessary surgical complications. Therefore, a noninvasive and reliable evaluation method is needed to determine tumor response after nCRT. MRI plays a crucial role in the initial staging of rectal cancer and in reassessing tumor response to nCRT. At present, the evaluation methods mainly include conventional MRI, functional MRI and MRI based on artificial intelligence prediction model. This paper comprehensively elaborated the research progress of the above three evaluation methods in predicting tumor response after neoadjuvant therapy for locally advanced rectal cancer.
[Keywords] rectal cancer；neoadjuvant chemoradiotherapy；tumor response；pathological complete response；magnetic resonance imaging；functional magnetic resonance imaging；artificial intelligence prediction model；review

LIU Dan1   ZHANG Shengchao2*  

1 Shanxi Medical University, Taiyuan 030001, China

2 Department of MRI, Taiyuan Second People's Hospital, Taiyuan 030002, China

*Zhang SC, E-mail: tyzsc163@qq.com

Conflicts of interest   None.

Received  2022-05-05
Accepted  2022-08-26
DOI: 10.12015/issn.1674-8034.2022.09.039
Cite this article as: Liu D, Zhang SC. Progress of MRI in predicting of the tumor response after neoadjuvant chemoradiotherapy for rectal cancer[J]. Chin J Magn Reson Imaging, 2022, 13(9): 163-166. DOI:10.12015/issn.1674-8034.2022.09.039.

[1]
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
Granata V, Grassi R, Fusco R, et al. Current status on response to treatment in locally advanced rectal cancer: what the radiologist should know[J]. Eur Rev Med Pharmacol Sci, 2020, 24(23): 12050-12062. DOI: 10.26355/eurrev_202012_23994.
[3]
Wang S, Ye YJ. Research progress of colorectal surgery in 2021 and future prospects[J]. Chin J Gastrointest Surg, 2022(1): 22-29. DOI: 10.3760/cma.j.cn441530-20211216-00502.
[4]
Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and Meta-analysis of treatment outcomes[J]. Ann Surg, 2020, 271(3): 440-448. DOI: 10.1097/SLA.0000000000003471.
[5]
Yang J, Wang W, Luo Y, et al. Effect of pathological complete response after neoadjuvant chemoradiotherapy on postoperative complications of rectal cancer: a systematic review and meta-analysis[J]. Tech Coloproctol, 2022, 26(3): 163-174. DOI: 10.1007/s10151-021-02564-y.
[6]
Liu S, Zhong GX, Zhou WX, et al. Can endorectal ultrasound, MRI, and mucosa integrity accurately predict the complete response for mid-low rectal cancer after preoperative chemoradiation? A prospective observational study from a single medical center[J]. Dis Colon Rectum, 2018, 61(8): 903-910. DOI: 10.1097/DCR.0000000000001135.
[7]
van der Sluis FJ, Couwenberg AM, Bock GHD, et al. Population-based study of morbidity risk associated with pathological complete response after chemoradiotherapy for rectal cancer[J]. Br J Surg, 2020, 107(1): 131-139. DOI: 10.1002/bjs.11324.
[8]
Kalisz KR, Enzerra MD, Paspulati RM. MRI evaluation of the response of rectal cancer to neoadjuvant chemoradiation therapy[J]. Radiographics, 2019, 39(2): 538-556. DOI: 10.1148/rg.2019180075.
[9]
Wang PP, Deng CL, Wu B. Magnetic resonance imaging-based artificial intelligence model in rectal cancer[J]. World J Gastroenterol, 2021, 27(18): 2122-2130. DOI: 10.3748/wjg.v27.i18.2122.
[10]
Lutsyk M, Awawda M, Gourevich K, et al. Tumor volume as predictor of pathologic complete response following neoadjuvant chemoradiation in locally advanced rectal cancer[J]. Am J Clin Oncol, 2021, 44(9): 482-486. DOI: 10.1097/COC.0000000000000846.
[11]
Liu WX, Li YQ, Zhu H, et al. The relationship between primary gross tumor volume and tumor response of locally advanced rectal cancer: pGTV as a more accurate tumor size indicator[J]. J Invest Surg, 2021, 34(2): 181-190. DOI: 10.1080/08941939.2019.1615153.
[12]
Nahas SC, Rizkallah Nahas CS, Sparapan Marques CF, et al. Pathologic complete response in rectal cancer: can we detect it? lessons learned from a proposed randomized trial of watch-and-wait treatment of rectal cancer[J]. Dis Colon Rectum, 2016, 59(4): 255-263. DOI: 10.1097/DCR.0000000000000558.
[13]
Jang JK, Choi SH, Park SH, et al. MR tumor regression grade for pathological complete response in rectal cancer post neoadjuvant chemoradiotherapy: a systematic review and meta-analysis for accuracy[J]. Eur Radiol, 2020, 30(4): 2312-2323. DOI: 10.1007/s00330-019-06565-2.
[14]
Achilli P, Magistro C, Abd El Aziz MA, et al. Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world[J]. Int J Cancer, 2022, 151(1): 120-127. DOI: 10.1002/ijc.33975.
[15]
Kalisz KR, Enzerra MD, Paspulati RM. MRI evaluation of the response of rectal cancer to neoadjuvant chemoradiation therapy[J]. Radiographics, 2019, 39(2): 538-556. DOI: 10.1148/rg.2019180075.
[16]
Yang YY, Zhang K, Zhang LN, et al. MR diffusion weighted imaging: application in soft tissue tumors[J]. Chin J Magn Reson Imaging, 2021, 12(10): 121-124. DOI: 10.12015/issn.1674-8034.2021.10.032.
[17]
Napoletano M, Mazzucca D, Prosperi E, et al. Locally advanced rectal cancer: qualitative and quantitative evaluation of diffusion-weighted magnetic resonance imaging in restaging after neoadjuvant chemo-radiotherapy[J]. Abdom Radiol (NY), 2019, 44(11): 3664-3673. DOI: 10.1007/s00261-019-02012-4.
[18]
Chandramohan A, Siddiqi UM, Mittal R, et al. Diffusion weighted imaging improves diagnostic ability of MRI for determining complete response to neoadjuvant therapy in locally advanced rectal cancer[J/OL]. Eur J Radiol Open, 2020, 7 [2022-05-05]. https://linkinghub.elsevier.com/retrieve/pii/S2352-0477(20)30012-5. DOI: 10.1016/j.ejro.2020.100223.
[19]
Popita AR, Lisencu C, Rusu A, et al. MRI evaluation of complete and near-complete response after neoadjuvant therapy in patients with locally advanced rectal cancer[J/OL]. Diagnostics (Basel), 2022, 12(4) [2022-05-05]. https://doi.org/10.3390/diagnostics12040921. DOI: 10.3390/diagnostics12040921.
[20]
Yuan Y, Pu H, Chen GW, et al. Diffusion-weighted MR volume and apparent diffusion coefficient for discriminating lymph node metastases and good response after chemoradiation therapy in locally advanced rectal cancer[J]. Eur Radiol, 2021, 31(1): 200-211. DOI: 10.1007/s00330-020-07101-3.
[21]
Bates DDB, Golia Pernicka JS, Fuqua JL, et al. Diagnostic accuracy of b800 and b1500 DWI-MRI of the pelvis to detect residual rectal adenocarcinoma: a multi-reader study[J]. Abdom Radiol (NY), 2020, 45(2): 293-300. DOI: 10.1007/s00261-019-02283-x.
[22]
Jang S, Lee JM, Yoon JH, et al. Reduced field-of-view versus full field-of-view diffusion-weighted imaging for the evaluation of complete response to neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer[J]. Abdom Radiol (NY), 2021, 46(4): 1468-1477. DOI: 10.1007/s00261-020-02763-5.
[23]
Zhao MJ, Zhao LH, Yang H, et al. Apparent diffusion coefficient for the prediction of tumor response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer[J/OL]. Radiat Oncol, 2021, 16(1) [2022-05-05]. https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01738-6. DOI: 10.1186/s13014-020-01738-6.
[24]
Chen K, She HL, Wu T, et al. Comparison of percentage changes in quantitative diffusion parameters for assessing pathological complete response to neoadjuvant therapy in locally advanced rectal cancer: a meta-analysis[J]. Abdom Radiol (NY), 2021, 46(3): 894-908. DOI: 10.1007/s00261-020-02770-6.
[25]
Xu QY, Xu YY, Sun HL, et al. Quantitative intravoxel incoherent motion parameters derived from whole-tumor volume for assessing pathological complete response to neoadjuvant chemotherapy in locally advanced rectal cancer[J]. J Magn Reson Imaging, 2018, 48(1): 248-258. DOI: 10.1002/jmri.25931.
[26]
Wen L, Hou J, Zhou JM, et al. Intravoxel incoherent motion diffusion-weighted imaging for discriminating the pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J/OL]. Sci Rep, 2017, 7(1) [2022-05-05]. https://doi.org/10.1038/s41598-017-09227-9. DOI: 10.1038/s41598-017-09227-9.
[27]
Hu HB, Jiang HJ, Wang S, et al. 3.0 T MRI IVIM-DWI for predicting the efficacy of neoadjuvant chemoradiation for locally advanced rectal cancer[J]. Abdom Radiol (NY), 2021, 46(1): 134-143. DOI: 10.1007/s00261-020-02594-4.
[28]
Li H, Yuan Y, Chen XL, et al. Value of intravoxel incoherent motion for assessment of lymph node status and tumor response after chemoradiation therapy in locally advanced rectal cancer[J/OL]. Eur J Radiol, 2022, 146 [2022-05-05]. https://doi.org/10.1016/j.ejrad.2021.110106. DOI: 10.1016/j.ejrad.2021.110106.
[29]
Meyer HJ, Höhn AK, Woidacki K, et al. Associations between IVIM histogram parameters and histopathology in rectal cancer[J]. Magn Reson Imaging, 2021, 77: 21-27. DOI: 10.1016/j.mri.2020.12.008.
[30]
Yang LQ, Xia CC, Zhao J, et al. The value of intravoxel incoherent motion and diffusion kurtosis imaging in the assessment of tumor regression grade and T stages after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer[J/OL]. Eur J Radiol, 2021, 136 [2022-05-05]. https://doi.org/10.1016/j.ejrad.2020.109504. DOI: 10.1016/j.ejrad.2020.109504.
[31]
Zhu HB, Zhang XY, Zhou XH, et al. Assessment of pathological complete response to preoperative chemoradiotherapy by means of multiple mathematical models of diffusion-weighted MRI in locally advanced rectal cancer: a prospective single-center study[J]. J Magn Reson Imaging, 2017, 46(1): 175-183. DOI: 10.1002/jmri.25567.
[32]
Liang CY, Chen MD, Zhao XX, et al. Multiple mathematical models of diffusion-weighted magnetic resonance imaging combined with prognostic factors for assessing the response to neoadjuvant chemotherapy and radiation therapy in locally advanced rectal cancer[J]. Eur J Radiol, 2019, 110: 249-255. DOI: 10.1016/j.ejrad.2018.12.005.
[33]
Granata V, Fusco R, Reginelli A, et al. Diffusion kurtosis imaging in patients with locally advanced rectal cancer: current status and future perspectives[J]. J Int Med Res, 2019, 47(6): 2351-2360. DOI: 10.1177/0300060519827168.
[34]
Lu WR, Yang XY, Qiu Q, et al. Research progress of diffusion kurtosis imaging in rectal cancer[J]. Int J Med Radiol, 2022, 45(2): 184-188. DOI: 10.19300/j.2022.Z18919.
[35]
Hu FX, Tang W, Sun YQ, et al. The value of diffusion kurtosis imaging in assessing pathological complete response to neoadjuvant chemoradiation therapy in rectal cancer: a comparison with conventional diffusion-weighted imaging[J]. Oncotarget, 2017, 8(43): 75597-75606. DOI: 10.18632/oncotarget.17491.
[36]
Bates DDB, Mazaheri Y, Lobaugh S, et al. Evaluation of diffusion kurtosis and diffusivity from baseline staging MRI as predictive biomarkers for response to neoadjuvant chemoradiation in locally advanced rectal cancer[J]. Abdom Radiol (NY), 2019, 44(11): 3701-3708. DOI: 10.1007/s00261-019-02073-5.
[37]
Li DD, Cui YF, Hou LN, et al. Diffusion kurtosis imaging-derived histogram metrics for prediction of resistance to neoadjuvant chemoradiotherapy in rectal adenocarcinoma: preliminary findings[J/OL]. Eur J Radiol, 2021, 144 [2022-05-05]. https://doi.org/10.1016/j.ejrad.2021.109963. DOI: 10.1016/j.ejrad.2021.109963.
[38]
Zhou ZP, Tang RJ, Tan XJ, et al. Correlation between dynamic contrast-enhanced MRI and tumor angiogenesis in rectal cancer[J]. J Med Imaging, 2017, 27(10): 1953-1957.
[39]
Jiang HJ, Zhu YQ. Prediction and evaluation value of functional imaging technique in neoadjuvant chemoradiotherapy of locally advanced rectal cancer[J]. Chin J Radiat Oncol, 2018, 27(10): 945-948. DOI: 10.3760/cma.j.issn.1004-4221.2018.10.016.
[40]
Petrillo A, Fusco R, Petrillo M, et al. DCE-MRI time-intensity curve visual inspection to assess pathological response after neoadjuvant therapy in locally advanced rectal cancer[J]. Jpn J Radiol, 2018, 36(10): 611-621. DOI: 10.1007/s11604-018-0760-1.
[41]
Ciolina M, Caruso D, de Santis D, et al. Dynamic contrast-enhanced magnetic resonance imaging in locally advanced rectal cancer: role of perfusion parameters in the assessment of response to treatment[J]. Radiol Med, 2019, 124(5): 331-338. DOI: 10.1007/s11547-018-0978-0.
[42]
Gollub MJ, Blazic I, Felder S, et al. Value of adding dynamic contrast-enhanced MRI visual assessment to conventional MRI and clinical assessment in the diagnosis of complete tumour response to chemoradiotherapy for rectal cancer[J]. Eur Radiol, 2019, 29(3): 1104-1113. DOI: 10.1007/s00330-018-5719-1.
[43]
Yeo DM, Oh SN, Choi MH, et al. Histogram analysis of perfusion parameters from dynamic contrast-enhanced MR imaging with tumor characteristics and therapeutic response in locally advanced rectal cancer[J/OL]. Biomed Res Int, 2018, 2018 [2022-05-05]. DOI: 10.1155/2018/3724393.
[44]
Li JP, Mao L, Zhou XT, et al. Progress of MRI in evaluating the efficacy of neoadjuvant therapy for rectal cancer[J]. Chin J Magn Reson Imaging, 2021, 12(4): 121-124. DOI: 10.12015/issn.1674-8034.2021.04.031.
[45]
Fu J, Zhong XR, Li N, et al. Deep learning-based radiomic features for improving neoadjuvant chemoradiation response prediction in locally advanced rectal cancer[J/OL]. Phys Med Biol, 2020, 65(7) [2022-05-05]. https://doi.org/10.1088/1361-6560/ab7970. DOI: 10.1088/1361-6560/ab7970.
[46]
Yi XP, Pei Q, Zhang YM, et al. MRI-based radiomics predicts tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer[J/OL]. Front Oncol, 2019, 9 [2022-05-05]. https://doi.org/10.3389/fonc.2019.00552. DOI: 10.3389/fonc.2019.00552.
[47]
Li ZY, Wang XD, Li M, et al. Multi-modal radiomics model to predict treatment response to neoadjuvant chemotherapy for locally advanced rectal cancer[J]. World J Gastroenterol, 2020, 26(19): 2388-2402. DOI: 10.3748/wjg.v26.i19.2388.
[48]
Wan L, Sun Z, Peng W, et al. Selecting candidates for organ-preserving strategies after neoadjuvant chemoradiotherapy for rectal cancer: development and validation of a model integrating MRI radiomics and pathomics[J/OL]. J Magn Reson Imaging, 2022 [2022-05-05]. https://doi.org/10.1002/jmri.28108. DOI: 10.1002/jmri.28108.
[49]
Wang J, Chen JJ, Zhou RZ, et al. Machine learning-based multiparametric MRI radiomics for predicting poor responders after neoadjuvant chemoradiotherapy in rectal Cancer patients[J/OL]. BMC Cancer, 2022, 22(1) [2022-05-05]. https://doi.org/10.1186/s12885-022-09518-z. DOI: 10.1186/s12885-022-09518-z.
[50]
Bordron A, Rio E, Badic B, et al. External validation of a radiomics model for the prediction of complete response to neoadjuvant chemoradiotherapy in rectal cancer[J/OL]. Cancers, 2022, 14(4) [2022-05-05]. https://doi.org/10.3390/cancers14041079. DOI: 10.3390/cancers14041079.

PREV Application progress of radiogenomics in the prediction of liver metastasis gene mutations in colorectal cancer
NEXT The latest research progress of functional MRI in traumatic cartilage injury of ankle joint
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn